Phase 2a Data Show that GLY-200 Treatment Led to Significant Reductions in Postprandial Glucose and Body Weight in Patients with Type 2 Diabetes Phase 1 Biomarker Results Were Consistent with those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results